Choroidal metastasis of non-small cell lung cancer that responded to gefitinib.
Choroidal metastasis of non-small cell lung cancer that responded to gefitinib.
复制标题
DOI：
10.1155/2013/213124
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Tatsumi K
中科院分区：
文献类型：
--
作者：
Shimomura I;Tada Y;Miura G;Suzuki T;Matsumura T;Tsushima K;Terada J;Kurimoto R;Sakaida E;Sekine I;Takiguchi Y;Yamamoto S;Tatsumi K
一名52岁的日本女性出现视觉症状，包括左侧肌松解、视力模糊、视野缩小和视力下降。目测显示脉络膜有转移性肿瘤。进一步检查确定肺腺癌为原发肿瘤。由于在活检标本中检测到表皮生长因子受体基因(EGFR)突变，吉非替尼开始治疗。在原发灶和转移灶均有显著反应。眼部症状改善，在治疗期间5个月内保持稳定，直至复发。这份报告证明吉非替尼对携带EGFR突变的肺腺癌脉络膜转移有效。
A 52-year-old Japanese woman presented with optical symptoms, including left-sided myodesopsia, blurred vision, narrowed visual field, and diminished visual acuity. Ocular evaluation revealed a metastatic tumor in the choroid. Further examinations identified pulmonary adenocarcinoma as the primary tumor. Because an epidermal growth factor receptor gene (EGFR) mutation was detected in a biopsy specimen, gefitinib treatment was initiated. Dramatic responses were obtained in the primary tumor and metastatic foci. Optical symptoms improved and remained stable for 5 months during the treatment, until relapse. This report demonstrates that gefitinib is effective for choroidal metastasis of pulmonary adenocarcinoma harboring an EGFR mutation.